Edition:
United States

Bayer AG (BAYGn.DE)

BAYGn.DE on Xetra

112.05EUR
20 Jul 2017
Change (% chg)

-- (--)
Prev Close
€112.05
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
1,966,523
52-wk High
€123.90
52-wk Low
€86.03

Select another date:

Mon, Jul 3 2017

BRIEF-Bayer invests 92 million euros in Animal Health production

* PROGRAM FOR EXPANDING SITE IN KIEL, GERMANY, UNTIL 2021 Source text - http://bit.ly/2tgZEcL Further company coverage: (Gdynia Newsroom)

UPDATE 1-Bayer files for Monsanto takeover approval with EU regulators

* EU Commission sets Aug 7 as provisional deadline for decision

Bayer to cut profit view on Brazil, consumer health setbacks

FRANKFURT Bayer said on Friday it would cut its full-year earnings forecast due to high inventories at crop protection distributors in Brazil and a weaker-than-expected consumer health business.

Bayer files for Monsanto takeover approval with EU regulators

FRANKFURT Bayer has filed a request for approval of its planned $66 billion takeover of U.S. seeds company Monsanto with European Union regulators, a spokesman for the German pharmaceuticals and pesticides maker said on Friday.

Bayer files for Monsanto takeover approval with EU regulators

FRANKFURT, June 30 Bayer has filed a request for approval of its planned $66 billion takeover of U.S. seeds company Monsanto with European Union regulators, a spokesman for the German pharmaceuticals and pesticides maker said on Friday.

UPDATE 2-Brazil, consumer health setbacks to dent Bayer's profit

* Consumer health business still weak (Adds details on industry woes in Brazil, analyst quote)

Bayer warns of weakness at crop protection in Brasil, consumer health

FRANKFURT, June 30 Bayer warned on Friday it would have to adjust its full-year outlook, citing excessively high inventory levels at crop protection customers in Brazil and a weaker-than-expected consumer health business.

BRIEF-Bayer enrolling patients into a global pulmonary arterial hypertension study

* Bayer- ‍Has enrolled first patient in a global phase IV study assessing clinical effects of riociguat in patients with pulmonary arterial hypertension​

UPDATE 1-BASF ready to snatch seed bargains as rivals sell assets

* Bayer to sell LibertyLink seed brands (Adds details on BASF's thinking, previous policy, rivals)

Monsanto profit tops expectations as soybean sales surge

U.S. seeds and agrochemicals company Monsanto Co , which is in the process of being bought by Germany's Bayer AG , reported a stronger-than-expected quarterly profit on Wednesday as record soybean plantings lifted seed sales. | Video

Select another date: